Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effet de l'interféron gamma en tant que traitement de l'immunosuppression post-agressive dans les unités de soins intensifs, un essai contrôlé bayésien randomisé en double aveugle versus placebo (INFINITY)

10 novembre 2026 mis à jour par: Assistance Publique - Hôpitaux de Paris

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

Aperçu de l'étude

Description détaillée

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).

We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.

Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.

Type d'étude

Interventionnel

Inscription (Estimé)

170

Phase

  • Phase 2
  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Limoges, France, 87000
      • Nancy, France
        • Recrutement
        • Pr Antoine Kimmoun
        • Contact:
      • Paris, France
        • Recrutement
        • Pr Dépret
        • Contact:
      • Paris, France, 75010
        • Recrutement
        • Pr Benjamin Chousterman
        • Contact:
      • Paris, France, 75013
        • Recrutement
        • Pr Constantin Michel
        • Contact:
      • Paris, France
        • Recrutement
        • Pr Megarbane
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patient ≥ 18 years old
  • SOFA score for first 24 hours post-admission ≥ 6
  • Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
  • mHLA-DR< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
  • Patient affiliated to a social security scheme
  • Written informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible

Exclusion Criteria:

  • Patient with estimated life expectancy of less than 3 months
  • Patients with a predicted remaining stay in intensive care < 72 hours
  • Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score < 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
  • Pregnant or breast-feeding women
  • Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
  • Patients on immunosuppressive therapy, including long-term corticosteroid therapy (>2.5mg/d prednisone equivalent)
  • Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
  • Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
  • People under court protection and protected adults

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: interferon gamma-1b injection

Patients randomized to the experimental arm will receive :

Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Comparateur placebo: Placebo injection

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
number of days alive without mechanical ventilation
Délai: on Day 28 after drug administration

number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day

on Day 28 after drug administration

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
Délai: Day 1 to Day 7 and at Day 28 post randomization

Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo.

Day 1 to Day 7 and at Day 28 post randomization
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
Délai: Day 0, Day 3 and at Day 7 post randomization

Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

Day 0, Day 3 and at Day 7 post randomization
mortality at Day 28 and Day 90 after randomization
Délai: Day 28 and Day 90 after randomization

Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

Day 28 and Day 90 after randomization
incidence of nosocomial infections during intensive care unit stay
Délai: from Day 0 to Day 28 (or the discharge from intensive care)

The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo

from Day 0 to Day 28 (or the discharge from intensive care)
number of days alive whithout antibiotic
Délai: Day 28 after drug administration

Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

Day 28 after drug administration
length of stay in intensive care between patients
Délai: from Day 0 to Day 28 (or the discharge from intensive care)

Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo

from Day 0 to Day 28 (or the discharge from intensive care)
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
Délai: From inclusion to Day 7

Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo

From inclusion to Day 7
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
Délai: Day 0, Day 3 and Day 7 after randomization

Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier.

Day 0, Day 3 and Day 7 after randomization
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo
Délai: Day 0 to Day 7 and at Day 28 post randomization

Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

Day 0 to Day 7 and at Day 28 post randomization

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Benjamin Chousterman, Professor, APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

24 février 2026

Achèvement primaire (Estimé)

1 mars 2029

Achèvement de l'étude (Estimé)

1 mai 2029

Dates d'inscription aux études

Première soumission

12 novembre 2024

Première soumission répondant aux critères de contrôle qualité

15 novembre 2024

Première publication (Réel)

19 novembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner